Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it
Yuanyuan Wang, Jiyuan Chen, Zhengjie Wu, et al.
British Journal of Pharmacology (2020) Vol. 178, Iss. 2, pp. 239-261
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile
Debasish Basak, Scott Arrighi, Yasenya Darwiche, et al.
Life (2021) Vol. 12, Iss. 1, pp. 48-48
Open Access | Times Cited: 125
Non-coding RNA-based regulation of inflammation
Milad Ashrafizadeh, Ali Zarrabi, Ebrahim Mostafavi, et al.
Seminars in Immunology (2022) Vol. 59, pp. 101606-101606
Closed Access | Times Cited: 70
Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells
Jinxiang Wang, Leli Zeng, Nisha Wu, et al.
Drug Resistance Updates (2023) Vol. 70, pp. 100985-100985
Open Access | Times Cited: 48
Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology
Milad Ashrafizadeh, Shahin Aghamiri, Shing Cheng Tan, et al.
Nano Today (2022) Vol. 45, pp. 101532-101532
Open Access | Times Cited: 60
Chiral Selenium Nanotherapeutics Regulates Selenoproteins to Attenuate Glucocorticoid‐Induced Osteoporosis
Zushuang Xiong, Hao Lin, Hong Li, et al.
Advanced Functional Materials (2023) Vol. 33, Iss. 17
Closed Access | Times Cited: 28
YAP antagonizes TEAD‐mediated AR signaling and prostate cancer growth
Xu Li, Shu Zhuo, Yong Suk Cho, et al.
The EMBO Journal (2023) Vol. 42, Iss. 4
Open Access | Times Cited: 25
Nanotherapeutics for prostate cancer treatment: A comprehensive review
Ruimin Hu, Lan Jin, Dinglin Zhang, et al.
Biomaterials (2024) Vol. 305, pp. 122469-122469
Closed Access | Times Cited: 9
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Xiang Gao, Haolin Zhao, Jiao Liu, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 8
MED12 and CDK8/19 modulate androgen receptor activity and enzalutamide response in prostate cancer
Chiara Andolfi, Caterina Bartolini, Elisa Morales, et al.
Endocrinology (2024) Vol. 165, Iss. 10
Open Access | Times Cited: 8
Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance
Zhipeng Wang, Jie Wang, Dengxiong Li, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101232-101232
Open Access | Times Cited: 1
MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis
Junqing Gan, Shan Liu, Yu Zhang, et al.
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 8, pp. 1290-1305
Open Access | Times Cited: 35
Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms
Himali Gujrati, Siyoung Ha, Bi‐Dar Wang
Cancers (2023) Vol. 15, Iss. 12, pp. 3140-3140
Open Access | Times Cited: 19
Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
Yang Li, Shimiao Zhu, Yutong Chen, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 4
Open Access | Times Cited: 18
Non-coding RNAs in enzalutamide resistance of castration-resistant prostate cancer
Ke Gao, Xiaoshun Li, Jianxin Ni, et al.
Cancer Letters (2023) Vol. 566, pp. 216247-216247
Closed Access | Times Cited: 16
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target
Xuming Zhou, Keqiang Chai, Hezhen Zhu, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 7
LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
Boya Zhang, Mingpeng Zhang, Chunyi Shen, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 10
Open Access | Times Cited: 37
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide
Junhong Li, Zhe Hong, Junyu Zhang, et al.
Oncogene (2024) Vol. 43, Iss. 10, pp. 744-757
Closed Access | Times Cited: 5
Single-cell and bulk RNA-sequence identify an immune-derived lncRNA-mRNA signature for predicting clinical outcomes and immunotherapeutic response of prostate cancer
Ren Liu, Hiocheng Un, Renxuan Lin, et al.
International Journal of Biological Macromolecules (2025), pp. 143014-143014
Open Access
Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular reactive oxygen species (ROS) in Prolactin-secreting Pituitary Adenoma
Linpeng Xu, Zhuowei Lei, Quanji Wang, et al.
Antioxidants and Redox Signaling (2024)
Closed Access | Times Cited: 4
Evaluating the Heterogeneity of Advanced Prostate Cancer by 18F‐DCFPyL and 18F‐FDG PET/CT in a Prospective Cohort
GuangHao Chen, Yuekai Li, ShangZhen Geng, et al.
The Prostate (2025)
Closed Access
Differential effects of jaboticaba peel extract administration on PCa progression in TRAMP mice depend on the androgenic status of the prostatic milieu and are driven by angiogenesis regulation
Beatriz Cristina Egídio de Rezende, A. Vecchi, Mário Roberto Maróstica, et al.
Food Research International (2025), pp. 116155-116155
Closed Access
Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15
Chenglin Han, Bin Yang, Yuxuan Deng, et al.
Chinese Medicine (2025) Vol. 20, Iss. 1
Open Access
Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
Jingwei Lin, Yingxin Cai, Zuomin Wang, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 9
Therapy resistance in prostate cancer: mechanism, signaling and reversal strategies
N.P. THAKUR, Pallavi Singh, Aditi Bagri, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 5, pp. 1110-1134
Open Access | Times Cited: 3
MicroRNAs as Promising Therapeutic Agents Against Prostate Cancer Resistant to Castration—Where Are We Now?
Mariana Ferreira, Mariana Morais, Rui Medeiros, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1347-1347
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top